Royal Jelly 1500 mg Equivalency
On sale on the US market (according to the DSLD)
NOW, food supplement from the US market
Royal Jelly 1500 mg Equivalency (NOW), a food supplement au code-barres 733739025654, is described by its US market label. The French and European rules we can apply to this label flag no particular point. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
No point flagged by the rules we apply.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- NOW
- Barcode
- 733739025654
- Form
- Capsule
- One serving
- « 1 Veg Capsule(s) »
- Servings
- number of servings per day not stated
- Other ingredients (in English, as written)
- Hypromellose, Rice Flour, Magnesium Stearate
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Royal Jelly | Ingredient of animal origin | 500 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Royal Jelly
Entered into DSLD on 25 July 2016. Withdrawn from the US market on 30 August 2023 (according to the DSLD).Same active composition.
Official label: Royal Jelly
Entered into DSLD on 22 May 2016. Withdrawn from the US market on 31 March 2016 (according to the DSLD).Same active composition.
Official label: Royal Jelly
Entered into DSLD on 23 January 2015. Withdrawn from the US market on 19 January 2016 (according to the DSLD).Same active composition.
Official label: Royal Jelly
Entered into DSLD on 25 February 2013. Withdrawn from the US market on 8 January 2015 (according to the DSLD).Same active composition.
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Royal Jelly
Read the warning, when it applies and the studies cited
ROYAL JELLY
Route of administration: Oral
Cautions and warnings
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.
Contraindications
Do not use if you have a history of asthma or allergies (TGA 2001; Leung et al. 1997; Harwood et al. 1996; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995; Bullock 1994).
Sources cited by Health Canada (8)
- Bullock RJ. Fatal royal-jelly induced asthma. Medical Journal of Australia 1994;160:44. PubMed Case report
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- TGA 2001: Australian Therapeutic Goods Administration. CMEC 28: Complementary Medicines Evaluation Committee, Extracted Ratified Minutes twenty-eight Meeting, 27-28 July 2001. Australian Government Department of Health and Aging, Sydney, Australia; 2001. [Accessed 2025 February 5]. Available from: https://www.tga.gov.au/sites/default/files/cmec-minutes-28.pdf
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
Known adverse reactions
Stop use if hypersensitivity/allergy occurs (Leung et al. 1997; Laporte et al. 1996; Thien et al. 1996; Leung et al. 1995; Peacock et al. 1995).
Sources cited by Health Canada (6)
- Laporte JR, Ibaanez L, Vendrell L, Ballarin E. Bronchospasm induced by royal jelly. Allergy 1996;51:440. PubMed
- Leung R, Ho A, Chan J, Choy D, Lai CK. Royal jelly consumption and hypersensitivity in the community. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1997;27(3):333-336. PubMed
- Leung R, Thien FC, Baldo B. Royal Jelly-induced asthma and anaphylaxis: clinical characteristics and immunologic correlations. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1995;96:1004-1007. PubMed Case report
- Peacock S, Muray V, Turton C. Respiratory distress and royal jelly. British Medical Journal 1995;311:1472. PubMed Case report
- Thien FC, Leung R, Baldo BA, Weiner JA, Plomley R, Czarny D. Asthma and anaphylaxis induced by royal jelly. Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology 1996;26(2):216-222. PubMed
- Harwood M, Harding S, Beasley R, Frankish PD. Asthma following royal jelly. The New Zealand Medical Journal 1996;109:325. PubMed Case report
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : NOW
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Royal Jelly 1500 mg Equivalency (NOW): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/733739025654-royal-jelly-1500-mg-equivalency-now, updated 25 March 2021.